‘Hijacker’ Drives Cancer in Some Patients with High-Risk Neuroblastoma
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including precision medicines.
The research involved investigators at St. Jude Children’s Research Hospital; Dana-Farber Cancer Institute, Boston; and the Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Neuroblastoma is a cancer of the sympathetic nervous system diagnosed annually in about 800 U.S. residents, primarily infants and young children. Although the long-term survival rate for patients with low-risk neuroblastoma is about 95 percent, the prognosis is worse for the 40 percent of patients with high-risk neuroblastoma. About half of those patients are alive five years after diagnosis.
Click here to read more.
International Conference on Dual Diagnosis and Disorders
Nov. 14-15, 2018; Melbourne, Austrailia
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2018
Nov. 15-17, 2018; Jacksonville, Fla.
2018 Mayo Clinic Multidisciplinary Spine Care Conference
Nov. 16-17, 2018; Amelia Island, Fla.
Craniofacial Surgery and Transfacial Approaches to the Skull Base
Nov. 30-Dec. 2, 2018; St. Louis
Comprehensive Endoscopic Endonasal Surgery of the Skull Base Course
Dec. 5-8, 2018; Pittsburgh